Related Experiment Videos
Carvedilol: a review of its use in chronic heart failure
Gillian M Keating1, Blair Jarvis
1Adis International Limited, Mairangi Bay, Auckland, New Zealand. demail@adis.co.nz
Insights
Carvedilol effectively treats chronic heart failure by improving left ventricular ejection fraction and reducing mortality. It is a preferred beta-blocker, offering significant benefits over metoprolol and placebo.
Area of Science:
- Cardiology
- Pharmacology
- Internal Medicine
Background:
- Carvedilol is an adrenoceptor antagonist with antioxidant and antiproliferative properties.
- Chronic heart failure (CHF) is a condition associated with impaired left ventricular ejection fraction (LVEF) and adverse cardiac remodeling.
- Existing treatments for CHF have limitations, necessitating the exploration of drugs with multifaceted mechanisms.
Purpose of the Study:
- To evaluate the efficacy of carvedilol in patients with chronic heart failure (CHF).
- To compare the effects of carvedilol with metoprolol and placebo on mortality, hospitalizations, and left ventricular remodeling.
- To assess the safety and tolerability of carvedilol in CHF patients.
Main Methods:
- Analysis of data from multiple clinical trials, including the US Carvedilol Heart Failure Trials Program, COMET, COPERNICUS, and CAPRICORN.
- Inclusion of patients with varying severities of CHF and left ventricular dysfunction post-myocardial infarction (MI).
- Comparison of carvedilol versus placebo and carvedilol versus metoprolol regarding mortality, cardiovascular hospitalizations, and LVEF.
Main Results:
- Carvedilol significantly improved LVEF in CHF patients, demonstrating greater increases than metoprolol in some studies.
- Carvedilol reduced all-cause mortality and cardiovascular hospitalizations compared to placebo in severe CHF (COPERNICUS) and post-MI patients (CAPRICORN).
- Mortality was significantly lower with carvedilol than with metoprolol in patients with mild to severe CHF (COMET).
Conclusions:
- Carvedilol's unique pharmacological profile, including alpha- and beta-adrenergic blockade and antioxidant effects, contributes to its benefits in CHF.
- Carvedilol improves ventricular function, reduces mortality and morbidity in mild to severe CHF, and is a standard treatment option.
- Carvedilol demonstrates superior outcomes compared to metoprolol in CHF, suggesting it may be a preferred beta-blocker.
Abstract:
Carvedilol (Dilatrend) blocks beta(1)-, beta(2)- and alpha(1)-adrenoceptors, and has antioxidant and antiproliferative effects. Carvedilol improved left ventricular ejection fraction (LVEF) in patients with chronic heart failure (CHF) in numerous studies. Moreover, significantly greater increases from baseline in LVEF were seen with carvedilol than with metoprolol in a double-blind, randomised study and in a meta-analysis. Carvedilol also reversed or attenuated left ventricular remodelling in patients with CHF and in those with left ventricular dysfunction after acute myocardial infarction (MI). Combined analysis of studies in the US Carvedilol Heart Failure Trials Program (patients had varying severities of CHF; n = 1094) revealed that mortality was significantly lower in carvedilol than in placebo recipients. In addition, the risk of hospitalisation for any cardiovascular cause was significantly lower with carvedilol than with placebo. Mortality was significantly lower with carvedilol than with metoprolol in patients with mild to severe CHF in the Carvedilol Or Metoprolol European Trial (COMET) [n = 3029]. The Carvedilol Prospective Randomised Cumulative Survival (COPERNICUS) trial (n = 2289) demonstrated that compared with placebo, carvedilol was associated with significant reductions in all-cause mortality and the combined endpoint of death or hospitalisation for any reason in severe CHF. All-cause mortality was reduced in patients who received carvedilol in addition to conventional therapy compared with those who received placebo plus conventional therapy in the Carvedilol Post-Infarct Survival Control in LV Dysfunction (CAPRICORN) trial (enrolling 1959 patients with left ventricular dysfunction following acute MI). Carvedilol was generally well tolerated in patients with CHF. Adverse events associated with the alpha- and beta-blocking effects of the drug occurred more commonly with carvedilol than with placebo, whereas placebo recipients were more likely to experience worsening heart failure. In conclusion, carvedilol blocks beta(1)-, beta(2)- and alpha(1)-adrenoceptors and has a unique pharmacological profile. It is thought that additional properties of carvedilol (e.g. antioxidant and antiproliferative effects) contribute to its beneficial effects in CHF. Carvedilol improves ventricular function and reduces mortality and morbidity in patients with mild to severe CHF, and should be considered a standard treatment option in this setting. Administering carvedilol in addition to conventional therapy reduces mortality and attenuates myocardial remodelling in patients with left ventricular dysfunction following acute MI. Moreover, mortality was significantly lower with carvedilol than with metoprolol in patients with mild to severe CHF, suggesting that carvedilol may be the preferred beta-blocker.